Urano F - Search Results

1

Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers.

Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, Matsunaga T. Toyoda H, et al. Among authors: urano f. Clin Gastroenterol Hepatol. 2006 Dec;4(12):1528-36. doi: 10.1016/j.cgh.2006.09.021. Clin Gastroenterol Hepatol. 2006. PMID: 17162244

2

Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.

Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, Oka H, Yamazaki O, Manabe T, Urano F, Chung H, Kudo M, Matsunaga T. Toyoda H, et al. Among authors: urano f. J Hepatol. 2008 Aug;49(2):223-32. doi: 10.1016/j.jhep.2008.04.013. Epub 2008 May 23. J Hepatol. 2008. PMID: 18571271

3

Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.

Honda T, Ishigami M, Masuda H, Ishizu Y, Kuzuya T, Hayashi K, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Katano Y, Goto H. Honda T, et al. Among authors: urano f. J Gastroenterol Hepatol. 2015 Feb;30(2):321-8. doi: 10.1111/jgh.12703. J Gastroenterol Hepatol. 2015. PMID: 25091027

4

Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction.

Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K, Goto H, Hirooka Y. Ishigami M, et al. Among authors: urano f. Clin Gastroenterol Hepatol. 2017 May;15(5):787-788. doi: 10.1016/j.cgh.2016.12.009. Epub 2016 Dec 21. Clin Gastroenterol Hepatol. 2017. PMID: 28013118 No abstract available.

5

Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.

Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K, Goto H, Hirooka Y. Ishigami M, et al. Among authors: urano f. J Gastroenterol Hepatol. 2017 Nov;32(11):1879-1886. doi: 10.1111/jgh.13779. J Gastroenterol Hepatol. 2017. PMID: 28258705

6

Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.

Honda T, Katano Y, Urano F, Murayama M, Hayashi K, Ishigami M, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H. Honda T, et al. Among authors: urano f. J Gastroenterol Hepatol. 2007 Jul;22(7):989-95. doi: 10.1111/j.1440-1746.2006.04773.x. J Gastroenterol Hepatol. 2007. PMID: 17608843

7

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study.

Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H; Peretinoin Study Group. Okita K, et al. J Gastroenterol. 2015 Feb;50(2):191-202. doi: 10.1007/s00535-014-0956-9. Epub 2014 Apr 13. J Gastroenterol. 2015. PMID: 24728665 Free PMC article. Clinical Trial.

8

Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B.

Hayashi K, Katano Y, Masuda H, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Hayashi K, et al. Among authors: urano f. Hepatol Res. 2013 Jun;43(6):580-8. doi: 10.1111/hepr.12005. Epub 2013 Jan 29. Hepatol Res. 2013. PMID: 23356752

9

Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C.

Honda T, Katano Y, Shimizu J, Ishizu Y, Doizaki M, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Honda T, et al. Among authors: urano f. Liver Int. 2010 Apr;30(4):527-37. doi: 10.1111/j.1478-3231.2009.02064.x. Epub 2009 Jun 12. Liver Int. 2010. PMID: 19523048

10

Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.

Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Hayashi K, et al. Among authors: urano f. J Med Virol. 2009 Mar;81(3):459-66. doi: 10.1002/jmv.21407. J Med Virol. 2009. PMID: 19152412

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

201 results

Search Page

Filters